Background
Materials and methods
Main aim
Data sources and search strategy
Inclusion criteria
Quality assessment
Data extraction and statistical analysis
Results
Author, year | Type of study | ARB used | Type of population | Duration of study | Number of patients | Doses, mg | ||||
---|---|---|---|---|---|---|---|---|---|---|
ARB | HCTZ + ARB | CTDN + ARB | ARB | HCTZ + ARB | CTDN + ARB | |||||
Fogari et al., 2010 [20] | Randomized, double-blind, parallel-group, up-titration, multicenter, multinational, phase III | Olmesartan | Moderate to severe hypertension, male or female patients, mean age 55.6 | 16 weeks | 285 | 556 | 40 | 40/12.5, 40/25 | ||
Benz et al., 1998 [21] | Randomized, double-blind, multiple dose, placebo controlled, multifactorial, parallel | Valsartan | Uncomplicated essential hypertension, male or female patients, mean age 52 (22-86) | 8 weeks | 198 (99, 99) | 379 (96, 92, 97, 94) | 80, 160 | 80/12.5, 80/25, 160/12.5, 160/25 | ||
Edes, 2009 [22] | Randomized, double-blind, parallel-group study | Candesartan | Mild to moderate primary hypertension, male or female patients, mean age 53 | 8 weeks, 4 weeks follow-up | 465 | 492 | 32 | 32/25 | ||
Kwon et al., 2013 [23] | Open-label, randomized, prospective cross-over study | Candesartan | Never treated primary hypertension, male or female patients, mean age 50 | 8 weeks | 25 (4 weeks) | 15 | 13 | 8 | 8/25 | 8/12.5 |
Lacourciere and Martin, 2002 [24] | Prospective, randomized, double-blind, parallel-group study | Telmisartan | Mild-to-moderate essential hypertension, male or female patients, mean age 54.1 (28-79) | 8 weeks | 167 | 160 | 40 | 40/12.5 | ||
Lacourciere et al., 2001 [25] | Multicenter, prospective, randomized, double-blind, parallel-group study | Telmisartan | Mild-to-moderate, essential hypertension and inadequate BP control, male or female patients, mean age 55.6 (20-79) | 8 weeks | 245 | 246 | 80 | 80/12.5 | ||
Lacourciere et al., 2005 [26] | Randomized, double blind, 3-arm, parallel group study | Valsartan | Stage 2 or 3 systolic hypertension (SBP ≥ 160 mmHg and ≤ 200 mmHg) with or without other CV risk factors, male or female patients, mean age 60.8 | 8 weeks | 261 | 513 (258, 255) | 80, 160 | 160/12.5, 160/25 | ||
Makita et al., 2009 [27] | Randomized, parallel-group study | Candesartan/valsartan vs telmisartan | Hypertensive outpatients treated with an ARB, candesartan or valsartan, male or female patients, mean age 69.3 | 12 weeks | 32 | 32 | 8 or 80 | 40/12.5 | ||
Rhee et al., 2015 [28] | Multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trial | Fimasartan | Mild to moderate primary hypertension, male or female patients, mean age 55.3 | 8 weeks | 88 | 175 | 60 | 60/12.5 | ||
Sachse et al., 2002 [29] | Multicenter, prospective, randomized, double-blind, parallel group study | Eprosartan | Mild to moderate primary hypertension, male or female patients mean age 58.7 | 8 weeks, 4 weeks follow-up | 157 | 152 | 600 | 600/12.5 | ||
MacKay et al., 1996 [32] | Multicenter, randomized, double-blind, parallel-group study | Losartan | Essential hypertension, male or female patients, mean age 55 (22-79) | 8 weeks, 4 weeks follow-up | 122 | 125, 114 | 50 | 50/6.25, 50/12.5 | ||
Sica et al., 2012 [33] | Phase 3, randomized, double-blind, factorial study | Azilsartan | Mild to moderate primary hypertension, male or female patients, mean age 57 | 8 weeks | 470 (155, 153, 162) | 928 (156, 147, 153, 154, 156, 162) | 20, 40, 80 | 20/12.5, 40/12.5, 80/12.5, 20/25, 40/25, 80/25 | ||
Cushman et al., 2012 [34] | Randomized, double-blind, forced-titration study | Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide | Primary hypertension, male or female patients, mean age 57 | 12 weeks | 364 | 355, 352 | 40/25 | 40/25, 80/25 | ||
Cushman et al., 2018 [35] | Randomized, double-blind, parallel-group study | Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide | Primary hypertension, male or female patients, mean age 57 | 8 weeks | 356 | 372, 357 | 40/25 | 40/25, 80/25 | ||
Neutel et al., 2017 [36] | Phase 3, randomized, parallel-group, open-label, multicenter, multinational study | Azilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazide | Stage 2 essential hypertension, male or female patients, mean age 58.5 (> 45) | 52 weeks | 419 | 418 | 40/25 | 80/25 |
Author, year | SBP | DBP | ||||
---|---|---|---|---|---|---|
ARB | HCTZ + ARB | CTDN + ARB | ARB | HCTZ + ARB | CTDN + ARB | |
Fogari et al., 2010 [20] | 168.1 ± 7.6 | 168.5 ± 8.4 | 104.5 ± 4.0 | 104.6 ± 4.2 | ||
Benz et al, 1998 [21] | 153.7 ± 14.4 153.5 ± 15.1 | 153.0 ± 14.0154.5 ± 15.4152.0 ± 14.2155.9 ± 14.8 | 101.5 ± 4.9 101.5 ± 4.8 | 101.0 ± 4.9 101.0 ± 4.5 100.4 ± 4.6 101.4 ± 4.8 | ||
Edes, 2009 [22] | 152.9 ± 12.8 | 154.0 ± 13.1 | 97.4 ± 5.6 | 97.5 ± 5.6 | ||
Kwon et al., 2013 [23] | 153 ± 13 | 128 ± 14 | 131 ± 12 | 94 ± 8 | 81 ± 11 | 84 ± 9 |
Lacourciere and Martin, 2002 [24] | 146.7 ± 12.7 | 147.1 ± 13.6 | 95.6 ± 4.8 | 95.7 ± 4.7 | ||
Lacourciere et al., 2001 [25] | 148.7 ± 16.1 | 148.9 ± 14.8 | 96.6 ± 5.2 | 96.4 ± 6.0 | ||
Lacourciere et al., 2005 [26] | 167.9 ± 8.0 | 167.4 ± 8.3 167.2 ± 7.9 | 93.2 ± 8.9 | 93.4 ± 9.6 93.7 ± 8.8 | ||
Makita et al., 2009 [27] | 160.6 ± 10.9 | 162.5 ± 10.9 | 84.5 ± 7.8 | 86.1 ± 8.7 | ||
Rhee et al., 2015 [28] | 150.8 ± 12.7 | 149.4 ± 11.9 | 96.8 ± 5.7 | 96.5 ± 5.428 | ||
Sachse et al., 2002 [29] | 156.0 ± 1.1 | 155.3 ± 1.1 | 98.9 ± 0.4 | 99.9 ± 0.4 | ||
MacKay et al., 1996 [32] | 152.2 | 152.6 151.3 | 100.9 | 101.2 101.7 | ||
Sica et al, 2012 [33] | 163 164 164 | 165 165 165 165 164 164 | 95 95 95 | 95 96 94 96 94 94 | ||
Cushman et al, 2012 [34] | 164.7 ± 9.9 | 164.9 ± 10.1 164.8 ± 9.8 | 95.2 ± 10.3 | 96.1 ± 9.8 95.9 ± 9.8 | ||
Cushman et al, 2018 [35] | 164.7 ± 10.4 | 165.2 ± 11.1 164.9 ± 10.5 | 96.1 ± 10.4 | 95.3 ± 10.5 95.4 ± 10.0 | ||
Neutel et al., 2017 [36] | 167.6 ± 7.0 | 168.2 ± 7.1 | 95.7 ± 9.6 | 95.7 ± 9.2 |